EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers

Julian Agin-Liebes, Alexander Haimovich iD, Rachel Griep, Nathan Galen Hatcher, Lihang Yao, Cheryl Waters, Shalini Padmanabhan, Roy N Alcalay

Movement Disorders · 2026

DOI: 10.1002/mds.70205 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, 2026. Verfasst von Julian Agin-Liebes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Columbia University Irving Medical Center, New York, USA. Hauptthemen laut MEDLINE: Glucosylceramidase, Psychosine, Parkinson Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Parkinson's Foundation, Michael J. Fox Foundation for Parkinson's Research, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GBA1 encodes the lysosomal enzyme glucocerebrosidase, with key substrates that include glucosylceramide and glucosylsphingosine. The E365K variant is the most common variant in GBA1 that is associated with Parkinson's disease (PD) but is not associated with Gaucher disease. Plasma glucosylsphingosine levels have previously been shown to be higher in GBA1 N409S heterozygous carriers, but its levels in E365K carriers are unknown.

Objective

The aim was to measure plasma glucosylsphingosine levels in GBA1 N409S, E365K, and L483P heterozygous mutation carriers with and without PD.

Methods

Glucosylsphingosine was quantified in plasma from 112 participants using liquid chromatography–tandem mass spectrometry targeted quantification.

Results

Plasma glucosylsphingosine concentration was significantly higher in N409S (0.59 ng/mL, p = 0.004), E365K (0.59 ng/mL, p = 0.01), and L483P (0.63 ng/mL, p = 0.003) heterozygotes compared to noncarriers (0.45 ng/mL), independent of disease status.

Conclusions

Elevated plasma glucosylsphingosine confirms reduced glucocerebrosidase function in E365K carriers. © 2026 Merck &Co. Inc. and The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucosylceramidasePsychosineParkinson DiseaseHumansHeterozygoteFemaleMutationMaleMiddle AgedAgedAdult

Stichwörter der Autor:innen

GBA1Parkinson's diseaseglucosylsphingospine

Substanzen

GlucosylceramidasePsychosineGBA protein, humansphingosyl beta-glucoside

Autor:innen und Institutionen

  • Department of Neurology, Columbia University Irving Medical Center, New York, USA.
  • Merck & Co., Inc, Rahway, New Jersey, USA.
  • The Michael J. Fox Foundation for Parkinson's Research, New York, USA.
  • Department of Neurology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel.
  • Tel Aviv Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

ORCID-Profile: Alexander Haimovich

Förderung

  • Parkinson's Foundation
  • Michael J. Fox Foundation for Parkinson's Research
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Agin-Liebes, J., Haimovich, A., Griep, R., Hatcher, N. G., Yao, L., Waters, C., Padmanabhan, S., & Alcalay, R. N. (2026). Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers. Movement Disorders. https://doi.org/10.1002/mds.70205

Vancouver

Agin-Liebes J, Haimovich A, Griep R, Hatcher NG, Yao L, Waters C, et al. Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers. Movement Disorders. 2026. doi:10.1002/mds.70205

BibTeX
@article{AginLiebes2026,
  author = {Agin-Liebes, Julian and Haimovich, Alexander and Griep, Rachel and Hatcher, Nathan Galen and Yao, Lihang and Waters, Cheryl and Padmanabhan, Shalini and Alcalay, Roy N},
  title = {Plasma Glucosylsphingosine in GBA1 E365K , N409S, and L483P Heterozygous Mutation Carriers},
  journal = {Movement Disorders},
  year = {2026},
  doi = {10.1002/mds.70205}
}
Kostenlos starten →